The present invention relates to a liquid oral care composition such as a mouthwash or mouth spray.
One embodiment discloses a liquid oral care composition including greater than 0.0% of an antimicrobial agent that is cetylpyridinium chloride (CPC), a cationic surfactant, an emulsifier, and less than 0.5% by weight of a thickener, such as hydroxyethylcellulose.
Another embodiment discloses a liquid oral care composition including 0.01% by weight to 0.4% by weight cetylpyridinium chloride (CPC), 0.005% by weight to 0.05% by weight PCA ethyl cocoyl arginate, 0.05% by weight to 2% by weight PEG-60 hydrogenated castor oil, and less than 0.5% by weight of hydroxyethylcellulose.
Another embodiment discloses a method of treating teeth including applying a liquid oral care composition including greater than 0.0% of an antimicrobial agent that is cetylpyridinium chloride (CPC), a cationic surfactant, an emulsifier, and less than 0.5% by weight of a thickener, such as hydroxyethylcellulose. In another embodiment, the cationic surfactant is PCA ethyl cocoyl arginate and the emulsifier is PEG-60 hydrogenated castor oil. In another embodiment, the composition includes 0.01% by weight to 0.4% by weight CPC, 0.005% by weight to 0.05% by weight PCA ethyl cocoyl arginate, 0.05% by weight to 2% by weight PEG-60 hydrogenated castor oil, and no more than 0.2% by weight hydroxyethylcellulose. In another embodiment, the composition includes 0.02% by weight to 0.1% by weight CPC, 0.005% by weight to 0.02% by weight PCA ethyl cocoyl arginate, 0.1% by weight to 0.5% by weight PEG-60 hydrogenated castor oil, and no more than 0.2% by weight hydroxyethylcellulose. In another embodiment, the composition includes 0.05% by weight to 0.1% by weight CPC, 0.005% by weight to 0.02% by weight PCA ethyl cocoyl arginate, 0.1% by weight to 0.5% by weight PEG-60 hydrogenated castor oil, and 0.1% by weight to 0.2% by weight hydroxyethylcellulose. In some embodiments, the composition is a mouthwash or mouth spray.
Dental plaque is formed by adsorption and propagation of harmful intraoral bacteria, such as Streptococcus mutans (“S mutans”), Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Prevotella intermedia, and Treponema denticola and the like on the surfaces of teeth. Dental plaque is a known cause of dental caries and gingivitis or periodontitis. Therefore, it is important to remove dental plaque and to prevent adhesion of it (plaque control) for oral sanitation.
One embodiment of an oral composition (e.g., a mouthwash or a mouth spray) comprises an antimicrobial agent, a cationic surfactant, an emulsifier, and a thickener. Preferably, the antimicrobial agent is cetylpyridinium chloride (CPC), the cationic surfactant is PCA ethyl cocoyl arginate, the emulsifier is PEG-60 hydrogenated castor oil, and the thickener is hydroxyethylcellulose. The oral care composition may optionally include additional surfactants, soothing or desensitizing agents, flavoring agents, sweetening agents, humectant agents, coloring agents, additional antimicrobial agents, binders or thickening agents, fluoride, preservatives, and water. The oral care composition, however, does not include an anionic surfactant because the anionic molecules of the anionic surfactant reduces the efficacy of CPC.
CPC has positively charged molecules that interact with negatively charged anionic sites on the cell walls of bacteria. Positively charged CPC can also bind to a tooth surface, which is also negatively charged. CPC can bind with and remain on the tooth surface for a long term. CPC can make an antimicrobial veil on the teeth and thereby help to prevent attachment of bacteria and accumulation of biofilm. Accordingly, CPC can help prevent dental plaque and dental caries by attacking bacteria and adsorbing to the oral mucosa or the surfaces of the teeth. However, when CPC is used in a formulation, other components of the formulation can reduce the ability of CPC to act as an antimicrobial agent. First, CPC is positively charged, so other negatively charged material in a formulation (e.g., anionic molecules) can react with the positively charged CPC molecules, which reduces the activity of CPC with bacteria and tooth surfaces thereby reducing the activity of CPC as an antimicrobial agent. Second, CPC also has characteristics of a surfactant. Therefore, CPC can form a micelle with other surfactants in a formulation. The formation of a micelle may interfere with the ability of CPC to attack the bacteria thereby reduce the antimicrobial activity.
The use of the cationic surfactant and the emulsifier in a formulation with CPC increases the antimicrobial effect of CPC in attacking bacteria and preventing dental plaque and dental caries. The cationic surfactant in the formulation competes with CPC to bind to anionic molecules in the formulation. That is, the cationic molecules of the cationic surfactant bind with anionic molecules in the formulation thereby preventing CPC from binding to anionic molecules in formulation. Accordingly, the CPC is free to attack bacteria and adsorb to the oral mucosa and surfaces of teeth. In the preferred embodiment, the cationic surfactant is PCA ethyl cocoyl arginate, which is an amino acid-based cationic surfactant derived from L-arginine, DL-pyrrolidone carboxylic acid and fatty acid. In other or additional embodiments, other suitable cationic surfactant may be used. These may include one or more of quaternary ammonium salts (e.g., benzalkonium chloride, benzethonium chloride, dimethyldioctadecylammonium chloride, dtearyldimethylbenzyl ammonium chloride, stearyltrimethylammonium chloride, cetyltrimethylaminium chloride, lauryltrimethylammonium chloride), bisbiguanides (e.g., chlorhexidine chloride, chlorhexidine acetate, chlorhexidine gluconate, alexidine hydrochloride, alexidine acetate, alexidine gluconate), or N-long-chain acyl basic amino acid lower alkyl esters or the salts thereof (e.g., pyrrolidonecaboxylic acid salt of N-Lauryl L-Arginine ethyl ester, pyrrolidonecaboxylic acid salt of N-Lauryl L-Arginine methyl ester, caboxylic acid salt of N-Palmitoyl L-Lysine methyl ester, hydrochloric acid salt of N-Cocoyl L-Arginine methyl ester, or laurylpyridinium chloride).
Emulsifiers are surfactants and are typically used to help dissolution of oil (e.g., flavor oil) in water. Emulsifiers therefore form a micelle with CPC when used together in a formulation. The structure of the micelle, which is determined based on the structure of the emulsifier (i.e., surfactant), determines the level of CPC inhibition. The structure of the micelle that results from the use of a poly(oxyethylene) hydrogenated castor oil that has an average molar number of ethylene oxide units added of 35 to 100 moles has been shown to be most effective in reducing the level of CPC inhibition. Moreover, in the preferred embodiment, the emulsifier is PEG-60 hydrogenated castor oil.
In addition to making the oral care composition thicker, the thickener in the formulation helps the oral care composition to stay on the gum tissue. The thickener also gives the oral care composition its moisturizing and gentle finish. In a preferred embodiment, the thickener is hydroxyethylcellulose, which is a polymer. Hydroxyethylcellulose is particularly comfortable for users with dry mouth or a generally sensitive mouth. The amount of hydroxyethylcellulose in the formulation is important because too much hydroxyethylcellulose can reduce the antimicrobial activity of CPC. It is believed that less hydroxyethylcellulose in the formulation shows a higher antibacterial effect than higher amounts of hydroxyethylcellulose. Other suitable thickeners may additionally or alternatively be used, such as nonionic polymers (e.g., methylcellulose, hydroxypropyl methylcellulose, hydroxypropylcellulose, crystsalline cellulose, microcrystalline cellulose, polyvinylpyrroridone) or cationic polymers (e.g., cationic guar gum derivatives and cationized xanthan gum).
The CPC is greater than 0.0% by weight, and in some embodiments, the CPC may measure between 0.01% and 0.4% by weight. In some embodiment, the CPC measures 0.02% by weight to 0.1% by weight. In some embodiments, the CPC measures 0.06% by weight to 0.1% by weight. In some embodiments, for example, the CPC may measure 0.05% by weight, 0.075% by weight, or 0.1% by weight. In some embodiments, the PCA ethyl cocoyl arginate measures 0.005% by weight to 0.05% by weight. In some embodiments, the PCA ethyl cocoyl arginate measures 0.005% by weight to 0.02% by weight. In some embodiments, the PCA ethyl cocoyl arginate measures 0.008% by weight to 0.012% by weight. In some embodiments, for example, the PCA ethyl cocoyl arginate may measure 0.005% by weight, 0.01% by weight, or 0.02% by weight. In some embodiments, the PEG-60 hydrogenated castor oil measures 0.05% by weight to 2% by weight. In some embodiments, the PEG-60 hydrogenated castor oil measures 0.1% by weight to 0.5% by weight. In some embodiments, the PEG-60 hydrogenated castor oil measures 0.12% by weight to 0.2% by weight. In some embodiments, for example, the PEG-60 hydrogenated castor oil may measure 0.1% by weight, 0.15% by weight, 0.2% by weight, 0.3% by weight, or 0.5% by weight. In some embodiments, the hydroxyethylcellulose may be less than 0.5% by weight. In some embodiments, the hydroxyethylcellulose may be not more than 0.3% by weight. In some embodiments, the hydroxyethylcellulose may be not more than 0.2% by weight. In some embodiments, for example, the hydroxyethylcellulose may measure 0.1% by weight or 0.2 by weight.
In one embodiment, the CPC may measure 0.01% by weight to 0.4% by weight, the PCA ethyl cocoyl arginate measures 0.005% by weight to 0.05% by weight, the PEG-60 hydrogenated castor oil measures 0.05% by weight to 2% by weight, and the hydroxyethylcellulose measures not more than 0.3% by weight. In another embodiment, the CPC measures 0.02% by weight to 0.1% by weight, the PCA ethyl cocoyl arginate measures 0.005% by weight to 0.02% by weight, the PEG-60 hydrogenated castor oil measures 0.1% by weight to 0.5% by weight, and the hydroxyethylcellulose measures not more than 0.2% by weight. In another embodiment, the CPC measures 0.06% by weight to 0.1% by weight, the PCA ethyl cocoyl arginate measures 0.008% by weight to 0.012% by weight, the PEG-60 hydrogenated castor oil measures 0.12% by weight to 0.2% by weight, and the hydroxyethylcellulose measures not more than 0.2% by weight.
The oral care compositions discussed herein may be prepared by any suitable method.
The results of the following experiments show an antibacterial effect and usability of the various formulations. For each experiment, the antibacterial effect is tested using a first base having an array of wells and a second base having an array of hydroxyapatite coated pegs. In this experiment, the first base included 96 wells and the second base included 96 pegs. Each of the hydroxyapatite coated pegs is positioned within a single well. First, the hydroxyapatite coated pegs are soaked in sterilized saliva for one hour to initiate acquired salivary pellicle formation. Then the hydroxyapatite coated pegs are washed with deionized water for one minute. Thereafter six of the hydroxyapatite coated pegs are soaked in each test sample (disclosed in the tables below) for two minutes. The hydroxyapatite coated pegs are again washed with deionized water for one minute, three times. Then S mutans in a brain heart infusion medium (BD) having 5% sucrose is applied to the wells and cultured for 24 hours in aerobic condition at 37.0° C. Finally, each biofilm is dissolved with 200 μL 1N NaOH. The amount of S mutans adsorbed on the hydroxyapatite coated of each peg is measured using UV-vis spectrophotometric optical density at a wavelength of 550 nm (OD550). The OD measurement is converted into a number representing the amount of S mutans in the remaining biofilm on the respective peg. Thereafter, an average amount of S mutans in the remaining biofilm after being treated with each sample was determined by taking an average of the data points for each of the six pegs used for each sample.
Also, the usability is tested for taste (e.g., bitterness) and texture (e.g., thickness) to evaluate usability. In particular, each of the test samples was subjected to an organoleptic test administered by trained scientists in a blind trial.
Experiment 1 used the tests above to determine the antibacterial efficacy and usability of two emulsifiers. All concentrations are measured in percent by weight. In particular, Experiment 1 tested whether PEG-40 hydrogenated castor oil or PEG-60 hydrogenated castor oil has better antibacterial effect and usability. As shown in Table 1, below, Sample 2 including PEG-60 hydrogenated castor oil had a greater antimicrobial effect than PEG-40 hydrogenated castor oil because less bacteria resulted. The taste for both was favorable.
Experiment 2 used the tests above to determine the antibacterial efficacy and usability of different concentrations of PCA ethyl cocoyl arginate. All concentrations are measured in percent by weight. As shown in Table 2, below, Sample 4 including 0.005% PCA ethyl cocoyl arginate had a greater antimicrobial effect than the samples having other concentrations because less bacteria resulted. Samples 5-8 including 0.01%, 0.02%, 0.05%, and 0.1% PCA ethyl cocoyl arginate, respectively, had a greater antimicrobial effect than Sample 3 having 0.0025% PCA ethyl cocoyl arginate because less bacteria resulted. Sample 8 having 0.1% PCA ethyl cocoyl arginate is not usable, however, because it has a bad or bitter taste.
Experiment 3 used the tests above to determine the antibacterial efficacy and usability of different concentrations of hydroxyethylcellulose. All concentrations are measured in percent by weight. As shown in Table 3, below, Sample 10 having a greater amount of hydroxyethylcellulose had a lesser antimicrobial effect than Sample 9 having less hydroxyethylcellulose. Also, Sample 10 was too thick and therefore not conducive for being used as a liquid oral composition.
Exemplary combinations of CPC, PCA ethyl cocoyl arginate, PEG-60 hydrogenated castor oil, and hydroxyethylcellulose in a formulation for an oral composition are given in the table below.
Although the invention has been described in detail with reference to certain preferred embodiments, variations and modifications exist within the scope and spirit of the invention.
This application claims the benefit of U.S. Provisional Patent Application No. 62/978,098, filed Feb. 18, 2020, which is incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
4233288 | Cornell | Nov 1980 | A |
4945087 | Talwar et al. | Jul 1990 | A |
5266306 | Ohtsuki et al. | Nov 1993 | A |
5496558 | Napolitano et al. | Mar 1996 | A |
5541165 | Turgeon | Jul 1996 | A |
5560906 | Scodari et al. | Oct 1996 | A |
5658554 | Fisher et al. | Aug 1997 | A |
6066345 | de Cock | May 2000 | A |
6117417 | Wicks et al. | Sep 2000 | A |
6159459 | Hunter et al. | Dec 2000 | A |
6177064 | de Troostembergh et al. | Jan 2001 | B1 |
6355229 | Adamy | Mar 2002 | B1 |
6471948 | Adamy et al. | Oct 2002 | B1 |
6579513 | Tashjian et al. | Jun 2003 | B1 |
6656920 | Fox et al. | Dec 2003 | B2 |
6706781 | Rajaiah et al. | Mar 2004 | B2 |
6828308 | Mastradonato et al. | Dec 2004 | B2 |
7198779 | Pinol et al. | Apr 2007 | B2 |
7501452 | Troha et al. | Mar 2009 | B2 |
7879877 | Nagamoto et al. | Feb 2011 | B2 |
7910089 | Uotani et al. | Mar 2011 | B2 |
8075924 | Loewy et al. | Dec 2011 | B2 |
8221724 | Hughes et al. | Jul 2012 | B2 |
8287842 | Katou et al. | Oct 2012 | B2 |
8367650 | Desjonqueres | Feb 2013 | B2 |
8444958 | Kamasaka et al. | May 2013 | B2 |
8506937 | Kho et al. | Aug 2013 | B2 |
8540970 | Rodriguez-Vilaboa | Sep 2013 | B2 |
8658139 | Cutler | Feb 2014 | B1 |
8858920 | Robinson et al. | Oct 2014 | B2 |
9044466 | Cohen et al. | Jun 2015 | B2 |
9138428 | Cohen et al. | Sep 2015 | B2 |
9149454 | Cooper et al. | Oct 2015 | B2 |
9192565 | Vogt et al. | Nov 2015 | B2 |
9198844 | Brisley | Dec 2015 | B2 |
9241885 | Roberge et al. | Jan 2016 | B2 |
20020168334 | Jacob et al. | Nov 2002 | A1 |
20030232858 | Barker et al. | Dec 2003 | A1 |
20040170576 | Grainger et al. | Sep 2004 | A1 |
20050100601 | Capps | May 2005 | A1 |
20050244346 | Nakao et al. | Nov 2005 | A1 |
20050250821 | Sewalt et al. | Nov 2005 | A1 |
20060094643 | Svirkin et al. | May 2006 | A1 |
20060134011 | Shanahan | Jun 2006 | A1 |
20060134020 | Robinson et al. | Jun 2006 | A1 |
20060204551 | Manley et al. | Sep 2006 | A1 |
20070031561 | Lakkis et al. | Feb 2007 | A1 |
20070274929 | Alexander et al. | Jul 2007 | A1 |
20080118446 | Jablow | May 2008 | A1 |
20080247972 | Conceicao | Oct 2008 | A1 |
20080317703 | Kawa et al. | Dec 2008 | A1 |
20090068122 | Pilch et al. | Mar 2009 | A1 |
20090081294 | Gin et al. | Mar 2009 | A1 |
20090104128 | Haley | Apr 2009 | A1 |
20090252690 | Behan et al. | Oct 2009 | A1 |
20090253804 | Marcy et al. | Oct 2009 | A1 |
20100022471 | Hanifl et al. | Jan 2010 | A1 |
20100098791 | Rodriguez-Vilaboa | Apr 2010 | A1 |
20100216830 | Iyoha et al. | Aug 2010 | A1 |
20110014136 | Kohli et al. | Jan 2011 | A1 |
20110020417 | Takeyama et al. | Jan 2011 | A1 |
20110104080 | Salloum et al. | May 2011 | A1 |
20110104081 | Scott et al. | May 2011 | A1 |
20110171342 | Phillips, III et al. | Jul 2011 | A1 |
20110189110 | Kohli et al. | Aug 2011 | A1 |
20120003162 | Mordas et al. | Jan 2012 | A1 |
20120003163 | Mordas et al. | Jan 2012 | A1 |
20130236400 | Lewus et al. | Sep 2013 | A1 |
20130251772 | Chopra et al. | Sep 2013 | A1 |
20130272971 | Pimenta et al. | Oct 2013 | A1 |
20130295041 | Kawa et al. | Nov 2013 | A1 |
20130344011 | Ramji et al. | Dec 2013 | A1 |
20130344120 | Scott et al. | Dec 2013 | A1 |
20140099347 | Prencipe | Apr 2014 | A1 |
20140155457 | Nho et al. | Jun 2014 | A1 |
20140187629 | Walker et al. | Jul 2014 | A1 |
20140271497 | Morgan | Sep 2014 | A1 |
20140286880 | Vogt et al. | Sep 2014 | A1 |
20150030547 | Liao et al. | Jan 2015 | A1 |
20150231060 | Okay | Aug 2015 | A1 |
20150320701 | Shigeki | Nov 2015 | A1 |
20150335549 | Patel et al. | Nov 2015 | A1 |
20150366794 | Cooper et al. | Dec 2015 | A1 |
20160008250 | Cohen et al. | Jan 2016 | A1 |
20160374352 | Modak et al. | Dec 2016 | A1 |
Number | Date | Country |
---|---|---|
101778618 | Jul 2010 | CN |
101780016 | Jul 2010 | CN |
101999990 | Apr 2011 | CN |
102639100 | Aug 2012 | CN |
103154726 | Jun 2013 | CN |
103385821 | Nov 2013 | CN |
001191 | Dec 2000 | EA |
0413427 | Feb 1991 | EP |
2100590 | Oct 2017 | EP |
2348370 | Oct 2000 | GB |
2354709 | Apr 2001 | GB |
H01153620 | Jun 1989 | JP |
H01246214 | Oct 1989 | JP |
H0259513 | Feb 1990 | JP |
H02169514 | Jun 1990 | JP |
H03151317 | Jun 1991 | JP |
H04173728 | Jun 1992 | JP |
H04202121 | Jul 1992 | JP |
H06239723 | Aug 1994 | JP |
H0725734 | Jan 1995 | JP |
H0725735 | Jan 1995 | JP |
H07133222 | May 1995 | JP |
H0812542 | Jan 1996 | JP |
H0848622 | Feb 1996 | JP |
H0825863 | Mar 1996 | JP |
H08217653 | Aug 1996 | JP |
H08259444 | Oct 1996 | JP |
H08268854 | Oct 1996 | JP |
H08268855 | Oct 1996 | JP |
2603465 | Apr 1997 | JP |
H0995457 | Apr 1997 | JP |
H1112142 | Jan 1999 | JP |
H1112168 | Jan 1999 | JP |
H1149625 | Feb 1999 | JP |
H1179961 | Mar 1999 | JP |
H11116452 | Apr 1999 | JP |
H11209254 | Aug 1999 | JP |
2000129299 | May 2000 | JP |
2001072562 | Mar 2001 | JP |
2001247446 | Sep 2001 | JP |
2001342500 | Dec 2001 | JP |
2002370956 | Dec 2002 | JP |
2003034619 | Feb 2003 | JP |
2003113059 | Apr 2003 | JP |
2006016309 | Jan 2006 | JP |
2006151876 | Jun 2006 | JP |
2006306768 | Nov 2006 | JP |
2007008843 | Jan 2007 | JP |
2007084471 | Apr 2007 | JP |
2008120753 | May 2008 | JP |
2008143870 | Jun 2008 | JP |
2008156288 | Jul 2008 | JP |
2009062285 | Mar 2009 | JP |
2009107989 | May 2009 | JP |
2010143843 | Jul 2010 | JP |
2011073970 | Apr 2011 | JP |
2011073996 | Apr 2011 | JP |
2011132169 | Jul 2011 | JP |
2011140454 | Jul 2011 | JP |
2011148706 | Aug 2011 | JP |
2011153138 | Aug 2011 | JP |
2011173873 | Sep 2011 | JP |
2012012303 | Jan 2012 | JP |
2012111732 | Jun 2012 | JP |
2012121833 | Jun 2012 | JP |
2012136504 | Jul 2012 | JP |
2012158580 | Aug 2012 | JP |
2012201632 | Oct 2012 | JP |
2012214402 | Nov 2012 | JP |
2013035760 | Feb 2013 | JP |
20000060197 | Oct 2000 | KR |
20040081936 | Sep 2004 | KR |
20080049177 | Jun 2008 | KR |
20110074232 | Jun 2011 | KR |
20130107397 | Oct 2013 | KR |
2013007035 | Sep 2013 | MX |
2009114589 | Dec 2010 | RU |
2432149 | Oct 2011 | RU |
2011117012 | Jan 2013 | RU |
2486891 | Jul 2013 | RU |
910333 | Apr 2003 | SI |
WO8907932 | Sep 1989 | WO |
WO9311754 | Jun 1993 | WO |
WO9418939 | Sep 1994 | WO |
WO02080946 | Oct 2002 | WO |
WO03002056 | Jan 2003 | WO |
WO2004071475 | Aug 2004 | WO |
WO2005039518 | May 2005 | WO |
WO2007009879 | Jan 2007 | WO |
WO2007066497 | Jun 2007 | WO |
WO2007134335 | Nov 2007 | WO |
WO2008013740 | Jan 2008 | WO |
WO2009032406 | Mar 2009 | WO |
WO2009098531 | Aug 2009 | WO |
WO2009106963 | Sep 2009 | WO |
WO2009117644 | Sep 2009 | WO |
WO2009135867 | Nov 2009 | WO |
WO2010121081 | Oct 2010 | WO |
WO2012021419 | Feb 2012 | WO |
WO2013062424 | May 2013 | WO |
WO2013096427 | Jun 2013 | WO |
WO2014165226 | Oct 2014 | WO |
Entry |
---|
Takahashi et al., “Feasibility of Emotion Recognition from Breath Gas Information”, Proceedings of the 2008 IEEE/ASME International Conference on Advanced Intelligent Mechatronics Jul. 2-5, 2008, Xi'an, China. (Year: 2008). |
Ialenti et al., “Hyaluronic acid inhibits polycation induced cellular responses,” Mediators of Inflammation, 1994, vol. 3, Issue 4, pp. 287-289. |
Jia et al., “New Formulation of Drug Controlled Release,” Chemical Industry Press, 2005, pp. 242-244 (6 pages including translation). |
Rölla et al., “Experiments with a toothpaste containing polydimethylsiloxan/triclosan,” Scandinavian Journal of Dental Research, 1993, vol. 101, No. 3, pp. 130-132. |
International Search Report and Written Opinion for Application No. PCT/US2021/017924 dated Apr. 26, 2021 (15 pages). |
Database GNPD Mintel; Nov. 28, 2018, “Regular Mouthwash”, XP093122935, Database accession No. 6166865 (3 pages). |
European Patent Office Supplementary Search Report for Application No. 21756589 dated Feb. 12, 2024 (11 pages). |
Number | Date | Country | |
---|---|---|---|
20210251870 A1 | Aug 2021 | US |
Number | Date | Country | |
---|---|---|---|
62978098 | Feb 2020 | US |